Heidelberg Pharma AG (XTER:HPHA) Short-Term Debt : €0.00 Mil (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Short-Term Debt?

Heidelberg Pharma AG's Short-Term Debt for the quarter that ended in Feb. 2024 was €0.00 Mil.

Heidelberg Pharma AG's quarterly Short-Term Debt increased from Aug. 2023 (€5.55 Mil) to Nov. 2023 (€5.65 Mil) but then declined from Nov. 2023 (€5.65 Mil) to Feb. 2024 (€0.00 Mil).

Heidelberg Pharma AG's annual Short-Term Debt increased from Nov. 2021 (€10.47 Mil) to Nov. 2022 (€15.79 Mil) but then declined from Nov. 2022 (€15.79 Mil) to Nov. 2023 (€5.65 Mil).

Heidelberg Pharma AG Short-Term Debt Historical Data

The historical data trend for Heidelberg Pharma AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Short-Term Debt Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Short-Term Debt

Get a 7-Day Free Trial

10.47

15.79

5.65

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Short-Term Debt	Get a 7-Day Free Trial															-	10.40	5.55	5.65	-

Heidelberg Pharma AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Heidelberg Pharma AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines